focus -WSS

focus

author：comprehensive 2025-08-28 08:47:00 - browse：84

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Cue Health's Covid

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

EPA limits use of carcinogenic gas for sterilizing medical devices

Q&A: Jennifer Adair on making gene therapy available globally

hotspot

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: CAR

Hepatitis C has a cure — but many Americans still lack access to it

Exact Sciences stock tumbles despite strong cancer detection sales

Medicare details structure of new drug price negotiation program

Cell therapy fails to slow type 1 diabetes, but safety is established

The cancer drug shortage isn’t new — and neither are the solutions

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Sports medicine is finally prioritizing gender equality

Why does health care cost so much? A reading guide

knowledge

HHS secretary Becerra pressed on Change HealthCare cyberattack

FDA advisers back CAR

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Change Healthcare outage fallout shows need for new oversight

First U.S. drug developed to treat liver disease MASH is approved

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

knowledge

leisure time

hotspot

leisure time